Compare Redwire Corporation (RDW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Redwire Corporation trades at $10.49 (market cap $2.67B), while State Street SPDR S&P Biotech ETF trades at $159.33. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| RDW | XBI | |
|---|---|---|
Market Cap | $2.67B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $25.90 | $169.55 |
52-Week Low | $5.06 | $93.43 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDW trades at $11.23, up 6.65% in the past 24 hours, with a bullish technical signal from moving averages and support near $11. The company reported Q2 2026 revenue growth of 90% year-over-year to $117.1 million and a record backlog of $542 million, but continues to post net losses, with a net income margin of -57.26% in 2026. Recent news highlights strategic investments in phased-array antenna technology and positive analyst sentiment with an 80% buy rating.
The stock offers growth potential driven by defense and space sector tailwinds and a expanding backlog, but high cash burn, persistent losses, and premium valuation (P/S of 4.59) pose significant risks. Execution on contracts and path to profitability are critical for sustaining the current bullish analyst outlook and price target of $12.17.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
